Effects of traditional Chinese medicine on treatment outcomes in severe COVID-19 patients: a single-centre study.
10.1016/S1875-5364(24)60565-0
- Author:
Yongjiu XIAO
1
;
Binbin LI
2
;
Chang LIU
3
,
4
;
Xiuyu HUANG
2
;
Ling MA
5
;
Zhirong QIAN
6
,
7
;
Xiaopeng ZHANG
8
;
Qian ZHANG
9
;
Dunqing LI
10
;
Xiaoqing CAI
5
;
Xiangyong YAN
8
;
Shuping LUO
11
;
Dawei XIANG
12
;
Kun XIAO
13
Author Information
1. Emergency Department, the 940(th) Hospital of Jiont Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China.
2. Scientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
3. School of Medicine, Nankai university, Tianjin 300000, China
4. Center of Pulmonary & Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing 100853, China.
5. Department of Cardiology, the 940(th) Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China.
6. Scientific Research Center, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China
7. Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou 350000, China. Electronic address: zrqian@hotmail.com.
8. Department of Traditional Chinese Medicine, the 940(th) Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China.
9. Department of Geriatric Diseases, the Seventh Medical Center of Chinese PLA General Hospital, Beijing 100700, China.
10. Health and Sport Administration, Muskingum University, Ohioan, USA.
11. Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China.
12. Department of Pulmonary and Critical Care Medicine, the 940(th) Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China. Electronic address: xiangdawei2020@163.com.
13. Center of Pulmonary & Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing 100853, China. Electronic address: xiaok301@foxmail.com.
- Publication Type:Journal Article
- Keywords:
COVID-19;
Clinical outcome;
Critically ill;
Novel coronavirus;
Pneumonia;
Traditional Chinese medicine
- MeSH:
Humans;
COVID-19;
Medicine, Chinese Traditional;
SARS-CoV-2;
Critical Illness;
Treatment Outcome
- From:
Chinese Journal of Natural Medicines (English Ed.)
2024;22(1):89-96
- CountryChina
- Language:English
-
Abstract:
As the search for effective treatments for COVID-19 continues, the high mortality rate among critically ill patients in Intensive Care Units (ICU) presents a profound challenge. This study explores the potential benefits of traditional Chinese medicine (TCM) as a supplementary treatment for severe COVID-19. A total of 110 critically ill COVID-19 patients at the Intensive Care Unit (ICU) of Vulcan Hill Hospital between Feb., 2020, and April, 2020 (Wuhan, China) participated in this observational study. All patients received standard supportive care protocols, with a subset of 81 also receiving TCM as an adjunct treatment. Clinical characteristics during the treatment period and the clinical outcome of each patient were closely monitored and analysed. Our findings indicated that the TCM group exhibited a significantly lower mortality rate compared with the non-TCM group (16 of 81 vs 24 of 29; 0.3 vs 2.3 person/month). In the adjusted Cox proportional hazards models, TCM treatment was associated with improved survival odds (P < 0.001). Furthermore, the analysis also revealed that TCM treatment could partially mitigate inflammatory responses, as evidenced by the reduced levels of proinflammatory cytokines, and contribute to the recovery of multiple organic functions, thereby potentially increasing the survival rate of critically ill COVID-19 patients.
